OBJECTIVES: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogs (SSAs). Selection criteria are a positive Octreoscan or a > 50% hormone level decrease after octreotide subcutaneous (s.c.) injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scanty. Thus, we evaluated whether plasma CgA response to OT could predict the clinical response to SSAs. METHODS: At diagnosis, 38 GEP-NET patients received octreotide 200 mu g s.c., with plasma CgA determination at 0, 3, and 6 h. Long-term SSA treatment was then given by monitoring symptomatic, biochemical, and objective responses, and survival. RESULTS: Basal plasma CgA levels were significantly higher in patients with functioning than non-functioning tumors (median (range): 220 (18-2,230) vs. 46 (25-8,610) U/l, P = 0.03) and in those with than without metastases (171 (18-8,610) vs. 43 (28-220) U/l, P = 0.04). CgA levels significantly correlated with WHO classification, clinical TNM staging, and Ki-67 proliferative index. After OT, CgA levels decreased from 146 (18-8,610) to 61 (10-8,535) U/l (basal and nadir values), P < 0.001. In patients responsive to OT, a successful objective response occurred in 21/31 patients (68%). Successful symptomatic response occurred in 13/18 patients (72%), biochemical response in 25/31 (81%), and objective response in 21/31 (68%). In the remaining seven unresponsive cases, with CgA decrement < 30%, disease progressed to death in six (86%). Median survival from enrollment was 48 months (6-138) in responsive and 6 (6-30) in unresponsive patients (P = 0.0005). CONCLUSIONS: In GEP-NETs, plasma CgA is a reliable marker, and a > 30% decrease after OT has a relevant prognostic meaning allowing the identification of the subgroup of patients most likely to be responsive to chronic SSAs.

Plasma chromogranin a response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors / S. Massironi, D. Conte, D. Sciola, M. Spampatti, C. Ciafardini, L.V. Valenti, R. Rossi, M. Peracchi. - In: THE AMERICAN JOURNAL OF GASTROENTEROLOGY. - ISSN 0002-9270. - 105:9(2010), pp. 2072-2078. [10.1038/ajg.2010.154]

Plasma chromogranin a response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors

D. Conte
Secondo
;
M. Spampatti;C. Ciafardini;L.V. Valenti;
2010

Abstract

OBJECTIVES: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogs (SSAs). Selection criteria are a positive Octreoscan or a > 50% hormone level decrease after octreotide subcutaneous (s.c.) injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scanty. Thus, we evaluated whether plasma CgA response to OT could predict the clinical response to SSAs. METHODS: At diagnosis, 38 GEP-NET patients received octreotide 200 mu g s.c., with plasma CgA determination at 0, 3, and 6 h. Long-term SSA treatment was then given by monitoring symptomatic, biochemical, and objective responses, and survival. RESULTS: Basal plasma CgA levels were significantly higher in patients with functioning than non-functioning tumors (median (range): 220 (18-2,230) vs. 46 (25-8,610) U/l, P = 0.03) and in those with than without metastases (171 (18-8,610) vs. 43 (28-220) U/l, P = 0.04). CgA levels significantly correlated with WHO classification, clinical TNM staging, and Ki-67 proliferative index. After OT, CgA levels decreased from 146 (18-8,610) to 61 (10-8,535) U/l (basal and nadir values), P < 0.001. In patients responsive to OT, a successful objective response occurred in 21/31 patients (68%). Successful symptomatic response occurred in 13/18 patients (72%), biochemical response in 25/31 (81%), and objective response in 21/31 (68%). In the remaining seven unresponsive cases, with CgA decrement < 30%, disease progressed to death in six (86%). Median survival from enrollment was 48 months (6-138) in responsive and 6 (6-30) in unresponsive patients (P = 0.0005). CONCLUSIONS: In GEP-NETs, plasma CgA is a reliable marker, and a > 30% decrease after OT has a relevant prognostic meaning allowing the identification of the subgroup of patients most likely to be responsive to chronic SSAs.
gastroenteropancreatic neuroendocrine tumors; somatostatin receptor scintigraphy; gastric carcinoid-tumors; interferon-alpha; follow-up; circulating markers; analog octreotide; grading system; management; efficacy
Settore MED/12 - Gastroenterologia
2010
Article (author)
File in questo prodotto:
File Dimensione Formato  
ajg2010154a.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 212.35 kB
Formato Adobe PDF
212.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/150956
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 50
social impact